Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies

European Journal of Internal Medicine

Volumn 24, Issue 6, 2013, Pages 486-491

  Cataland, Spero R ^a   Wu, Haifeng M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

ADAMTS13 activity; aHUS; Complement activation; Thrombotic microangiopathy; TTP

Indexed keywords

COMPLEMENT; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

BRAIN INJURY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; ENZYME ACTIVITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY INJURY; PLASMAPHERESIS; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ADAMTS13 ACTIVITY; AHUS; COMPLEMENT ACTIVATION; THROMBOTIC MICROANGIOPATHY; TTP;

ADAM PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; DIAGNOSIS, DIFFERENTIAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 84883557853     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2013.05.007     Document Type: Review

References (30)

1. H.M. Tsai Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes J Thromb Haemost 1 2003 625 631
2. A. Veyradier, B. Obert, A. Houllier, D. Meyer, and J.P. Girma Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases Blood 98 2001 1765 1772
3. H.M. Tsai, and E.C. Lian Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Engl J Med 339 1998 1585 1594 (Pubitemid 28536133)
4. H.M. Tsai Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura J Am Soc Nephrol 14 2003 1072 1081
5. R.A. Gruppo, and R.P. Rother Eculizumab for congenital atypical hemolytic-uremic syndrome N Engl J Med 360 2009 544 546
6. C. Licht, P. Muus, C. Legendre, K.W. Douglas, M. Hourmant, and Y. Delmas Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) previously receiving chronic plasma exchange/infusion (PE/PI): extension study results ASH annual meeting abstracts 118 2011 3303
7. L. Greenbaum, S. Babu, R.R. Furman, N. Sheerin, D. Cohen, and O. Gaber Eculizumab is an effective long-term treatment in patients with atypical hemolytic uremic syndrome (aHUS) resistant to plasma exchange/infusion (PE/PI): results of an extension study ASH annual meeting abstracts 118 2011 193
8. G. Remuzzi Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No J Thromb Haemost 1 2003 632 634
9. X.L. Zheng, R.M. Kaufman, L.T. Goodnough, and J.E. Sadler Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura Blood 103 2004 4043 4049 (Pubitemid 38685342)
10. P. Coppo, D. Bengoufa, A. Veyradier, M. Wolf, A. Bussel, and G.A. Millot Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement Medicine 83 2004 233 244 (Pubitemid 38955446)
11. J.A. Kremer Hovinga, S.K. Vesely, D.R. Terrell, B. Lammle, and J.N. George Survival and relapse in patients with thrombotic thrombocytopenic purpura Blood 115 2010 1500 1511
12. M.J. Jang, S.Y. Chong, I.H. Kim, J.H. Kim, C.W. Jung, and J.Y. Kim Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience Int J Hematol 93 2011 163 169
13. M. Matsumoto, C.L. Bennett, A. Isonishi, Z. Qureshi, Y. Hori, and M. Hayakawa Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan PLoS One 7 2012 e33029
14. P. Coppo, M. Schwarzinger, M. Buffet, A. Wynckel, K. Clabault, and C. Presne Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience PLoS One 5 2010 e10208
15. A.L. Sellier-Leclerc, V. Fremeaux-Bacchi, M.A. Dragon-Durey, M.A. Macher, P. Niaudet, and G. Guest Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome J Am Soc Nephrol 18 2007 2392 2400 (Pubitemid 47203855)
16. M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, and S. Gamba Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype Clin J Am Soc Nephrol 5 2010 1844 1859
17. K. Gulleroglu, K. Fidan, V.S. Hancer, U. Bayrakci, E. Baskin, and O. Soylemezoglu Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab Pediatr Nephrol 28 2013 827 830
18. H. Povey, R. Vundru, N. Junglee, and M. Jibani Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis Clin Nephrol 2013 [epud ahead of print]
19. G. Salem, J.M. Flynn, and S.R. Cataland Profound neurological injury in a patient with atypical hemolytic uremic syndrome Ann Hematol 92 2013 557 558
20. J.A. Hovinga, S.K. Vesely, D.R. Terrell, B. Lammle, and J.N. George Survival and relapse in patients with thrombotic thrombocytopenic purpura Blood 115 2010 1500 1511
21. S.R. Cataland, S. Yang, and H.M. Wu The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies Br J Haematol 157 2012 501 503
22. M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, and B. Brenner von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Engl J Med 339 1998 1578 1584 (Pubitemid 28536132)
23. G. Remuzzi, M. Galbusera, M. Noris, M.T. Canciani, E. Daina, and E. Bresin von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome Blood 100 2002 778 785 (Pubitemid 34832601)
24. R. Froehlich-Zahnd, J.N. George, S.K. Vesely, D.R. Terrell, K. Aboulfatova, and J.F. Dong Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura Haematology 97 2012 297 303
25. T. Raife, B. Atkinson, R. Montgomery, S. Vesely, and K. Friedman Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients Transfusion 44 2004 146 150 (Pubitemid 38236374)
26. C. Loirat, and V. Fremeaux-Bacchi Atypical hemolytic uremic syndrome Orphanet J Rare Dis 6 2011 60
27. V. Fremeaux-Bacchi, F. Fakhouri, A. Garnier, F. Bienaime, M.A. Dragon-Durey, and S. Ngo Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults Clin J Am Soc Nephrol 8 2013 554 562
28. M. Harboe, E.B. Thorgersen, and T.E. Mollnes Advances in assay of complement function and activation Adv Drug Deliv Rev 63 2011 976 987
29. M. Reti, P. Farkas, D. Csuka, K. Razso, A. Schlammadinger, and M.L. Udvardy Complement activation in thrombotic thrombocytopenic purpura J Thromb Haemost 10 2012 791 798
30. J. Zuber, F. Fakhouri, L.T. Roumenina, C. Loirat, and V. Fremeaux-Bacchi French Study Group for a HCG. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies Nat Rev Nephrol 8 2012 643 657